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INITIAL RESULTS OF TREATMENT WITH HYLAN G-F 20
AND CORTICOSTEROID
K.K. Briggs, L.M. Matheny, J.R. Steadman
Steadman Hawkins Research Foundation, Vail, CO
Purpose: Recent studies on the use of Hylan G-F 20 have shown
that improvement may be highly variable based on the time from
treatment, especially within the ﬁrst 12 weeks following treatment.
The purpose of this study is to document outcomes following a
treatment protocol in which corticosteroid is used in addition to
the initial Synvisc injection in a series of three injections.
Methods: 33 consecutive knees, in 26 patients were enrolled in
a prospective cohort study. There were 15 females and 11 males,
with an average age of 62.6 years (range: 22.2 - 81.7 years).
The study was IRB approved with informed patient consent. Pa-
tients who met the inclusion/exclusion criteria were enrolled. The
inclusion criteria were men or women aged 18 to 80 years with
a diagnosis of osteoarthritis of the knee. Diagnosis was based
on radiographic examination (Kellgren-Lawrence). Patients with
a prior synovectomy on the knee to be injected were excluded.
Patients were excluded if they had rheumatoid disease or any
other serious systemic disease, acute synovitis or excessive ef-
fusion, allergy to avian products/hyaluronan-based injection com-
ponents/corticosteroid injection, pregnant, previous arthroscopic
surgery within the last 6 months or had a joint infection within
the previous 3 months. Patients were given the standard course
of 3 (2 ml) weekly injections. At the ﬁrst injection, in addition to
the standard Hylan G-F 20 injection, corticosteroid was added.
The second and third injection did not include corticosteroid. At
1 week, 3 weeks, 6 weeks, and 6 months following the com-
pleted series of injections, the patients completed a form that
included the pain, stiffness, and physical function subscales of
the WOMAC score and a 10 point patient satisfaction question.
Results: Four patients (12%) required surgery prior to the 6
month time-point. No patient discontinued the injection series
due to a negative response to the injection. At week one, pa-
tients experienced a signiﬁcant decrease in the pain (p=0.01)
and stiffness (p=0.004) scale of the WOMAC. Both scores had
decreased by 50% at one week. The average patient satisfac-
tion score was 7.9. At week 3, there was signiﬁcant improvement
from preoperative scores in pain (p=0.001), stiffness (0.001), and
function (p=0.013). The total WOMAC decreased by 12 points
(p=0.008). The average patient satisfaction at week 3 was 7.9.
Although all scores continued to decrease, there was no signif-
icant difference in scores between 1 and 3 weeks. At week 6,
there was signiﬁcant improvement in preoperative scores for pain
(p=0.005), stiffness (0.001), and function (p=0.019). The average
patient satisfaction at week 6 was 7.2. There was no signiﬁcant
difference in scores between 6 weeks and 6 months. Patients’
average Tegner at 6 months was 2.7.
Conclusions: These early results showed a positive response
in the initial weeks following completion of the injection series.
There were no adverse reactions to the injections. While some
patients chose to undergo surgery, symptoms did not worsen in
most patients at 6 months.
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C. Klein, W. Liu, J. Qian, R. Jain, S. Dutta
Abbott Laboratories, Abbott Park, IL
Purpose: A controlled-release hydrocodone/acetaminophen
(HC/APAP CR) tablet (15/500 mg) is being developed for pa-
tient convenience. This study evaluated the pharmacokinetics of
HC/APAP CR tablets in healthy subjects.
Methods: This IRB-approved, two-part, single- and multiple-
dose(s), fasting and non-fasting, open-label, randomized
crossover study was conducted in 44 healthy adults. In Cohort
1, 24 subjects were randomized to receive a single dose of 1, 2
and 3 HC/APAP CR tablets and 3 doses of HC/APAP reference
tablets (10/325 mg) every 4 hours under fasting conditions. In
Cohort 2, 20 subjects were randomly assigned to 2 HC/APAP CR
tablets administered every 12 hours and 1 HC/APAP reference
tablet administered every 4 hours for 3 days. Washout intervals
of at least 5 days separated doses of each period.
Results: Following a single dose of 1, 2 and 3 HC/APAP CR
tablet(s), mean maximum plasma concentration (Cmax) ranged
from 13.3 to 36.8 ng/mL for HC and 2.01 to 6.68 µg/mL for APAP;
the area under the plasma concentration-time curve (AUC∞)
ranged from 232 to 658 ngh/mL for HC and 21.9 to 63.7 µgh/mL
for APAP. Systemic exposures (Cmax and AUC∞) of HC and
APAP increased proportionally with increasing doses. The mean
time to reach Cmax (Tmax) was 6.0-6.7 hours for HC and 1.1-1.3
hours for APAP. Following twice-daily dosing of 2 HC/APAP CR
tablets for 3 days, steady state for HC/APAP concentrations was
attained by 24 hours. The mean Cmax on Day 3 was 37.0 ng/mL
for HC and 4.96 µg/mL for APAP. The adverse event proﬁle was
consistent with that expected of opioid-naive subjects receiving
opioid-combination therapy.
Conclusions: Systemic exposures of HC and APAP demon-
strated a dose-proportional increase from 1 to 3 tablets. Steady-
state concentrations were reached by 24 hours with minimal
accumulation following twice-daily administration. The pharma-
cokinetics of HC/APAP CR tablets support a twice-daily dosage
regimen.
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STRUCTURAL-FUNCTIONAL STATE OF BONE LOSS OF
THE POSTMENOPAUSAL WOMEN WITH KNEE
OSTEOARTHRITIS
V. Povoroznjuk, N. Grygor’yeva
Institute of Gerontology AMS Ukraine, Kiev, Ukraine
Purpose: Aim of the study is to study the peculiarities of knee
osteoarthritis (OA) and structural-functional state of bone mass
in the women of postmenopausal period.
Methods: We’ve examined 277 health women aged of 50-74
years (mean age - 65,9±0,3 years) in postmenopausal period
with well-timed menopause, knee OA (I-III stages) and without
risk factors of osteoporosis.The diagnosis of OA was determined
according to the ACR criteria (1995), its stage - according to
Kellgren-Lawrence’s classiﬁcation. Investigation of bone state
was carried out using ultrasound bone densitometry method
by densitometer “Achilles+” (Lunar Corp., Madison, WI). Device
determined the speed of ultrasound spreading through bone
(SOS, m/s), broadband ultrasound attenuation (BUA, dB/MHz),
Stiffness Index (%), index T and index Z.
Results: This study have determined the data of state of bone
mass of the postmenopausal women in depend of age and
knee OA’ stage (Table 1). The higher indices of ultrasound
densitometry have been established in the patients, aged 60-69
years, with the initial stage of knee OA (1st stage) as compared
with the 2d and 3d ones and women of control group. We did not
ﬁnd the signiﬁcant differences of densitometry’s data in women,
aged 70-74 years with/without OA. It was founded that all women
with OA had the increased body mass. But in the women, aged
60-69 years with 2d and 3d stages of knee OA, which were
standardised on BMI with control group and women with 1d
stage of OA, the data of ultrasound densitometry were signiﬁcant
